Suppliers and packagers for generic pharmaceutical drug: FINGOLIMOD LAURYL SULFATE

FINGOLIMOD LAURYL SULFATE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Cycle	TASCENSO ODT	fingolimod lauryl sulfate	TABLET, ORALLY DISINTEGRATING;ORAL	214962	NDA	Cycle Pharmaceuticals Ltd	70709-062-30	3 BLISTER PACK in 1 CARTON (70709-062-30) / 10 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK	2023-02-01
Cycle	TASCENSO ODT	fingolimod lauryl sulfate	TABLET, ORALLY DISINTEGRATING;ORAL	214962	NDA	Cycle Pharmaceuticals Ltd	70709-065-30	3 BLISTER PACK in 1 CARTON (70709-065-30) / 10 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK	2023-02-01

Fingolimod Lauryl Sulfate: Key Supplier Landscape and Patent Analysis

Last updated: February 19, 2026

Fingolimod lauryl sulfate, a sphingosine-1-phosphate (S1P) receptor modulator, is the active pharmaceutical ingredient in Gilenya®, approved for treating relapsing forms of multiple sclerosis. The patent landscape surrounding its manufacture and the supply chain for key intermediates and the final API are critical considerations for market participants. This report analyzes the primary suppliers and relevant intellectual property impacting the production of fingolimod lauryl sulfate.

What are the primary manufacturing routes for Fingolimod Lauryl Sulfate?

The synthesis of fingolimod (2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol) involves several key steps, and its conversion to the lauryl sulfate salt adds a further stage. While specific proprietary manufacturing processes are closely guarded, common synthetic pathways often involve building the phenyl group and the propane-1,3-diol core separately, followed by their coupling and subsequent functionalization.

One common approach begins with readily available phenylacetonitrile derivatives. Alkylation and subsequent reduction steps can establish the ethylamine side chain. The propane-1,3-diol moiety can be synthesized through various routes, often involving epoxides or glycidol derivatives. The coupling of these two fragments, followed by chiral resolution or asymmetric synthesis to obtain the desired stereoisomer, is a critical juncture. The final step involves forming the lauryl sulfate salt by reacting fingolimod base with dodecyl sulfuric acid.

Variations in these routes focus on improving yield, reducing the number of steps, enhancing enantioselectivity, and minimizing impurity profiles. The choice of reagents, catalysts, and purification methods are significant factors influencing cost and scalability.

Who are the key API manufacturers for Fingolimod Lauryl Sulfate?

The manufacturing of Active Pharmaceutical Ingredients (APIs) for complex small molecules like fingolimod requires specialized expertise and Good Manufacturing Practice (GMP) compliance. The primary API manufacturers can be categorized into originator companies and contract development and manufacturing organizations (CDMOs) that supply generic versions or support the originator.

Originator Manufacturer:

• Novartis AG: As the originator of Gilenya®, Novartis maintains its own internal manufacturing capabilities or contracts with specific preferred partners for the production of fingolimod lauryl sulfate. Specific details of their manufacturing partners are often confidential.

Key CDMOs and Generic API Suppliers:

The landscape for generic fingolimod lauryl sulfate API suppliers is dynamic and influenced by patent expiries and regulatory approvals. Several CDMOs and specialized API manufacturers possess the capabilities to produce fingolimod lauryl sulfate. These include:

• Lonza Group AG: Lonza is a significant player in the custom API manufacturing space, known for its complex chemistry capabilities. They are a probable supplier for various pharmaceutical intermediates and finished APIs.
• WuXi AppTec Co. Ltd.: A leading global pharmaceutical, biopharmaceutical, and medical device outsourcing company, WuXi AppTec offers integrated capabilities from R&D to manufacturing, including complex small molecule APIs.
• Evonik Industries AG: Through its health care business line, Evonik provides custom manufacturing services for APIs and advanced intermediates, often focusing on complex synthetic routes.
• Piramal Pharma Solutions: This CDMO offers end-to-end solutions for drug substance development and manufacturing, including expertise in small molecule synthesis.
• Divi's Laboratories Limited: Divi's is a prominent Indian API manufacturer known for its large-scale production capabilities and cost-effectiveness, often serving the generic market.
• Laurus Labs Limited: Another Indian pharmaceutical company with strong API manufacturing expertise, Laurus Labs is recognized for its process development and commercial manufacturing capabilities.

The specific companies actively supplying fingolimod lauryl sulfate can fluctuate based on market demand, regulatory approvals for generic versions, and the expiry of key patents. Companies seeking to enter the market or secure their supply chain would need to conduct thorough due diligence on potential partners, including their regulatory track record, quality systems, and capacity.

What are the key intermediates and their suppliers?

The synthesis of fingolimod involves several critical intermediates. Identifying suppliers for these intermediates is crucial for supply chain security and cost management.

Key Synthetic Intermediates and Potential Supplier Categories:

The precise intermediates depend on the chosen synthetic route. However, common building blocks and their functionalized derivatives include:

1. 4-Octylphenylacetic acid derivatives: These can be the starting point for constructing the octylphenyl ethyl portion of the molecule.
   • Potential Suppliers: Fine chemical manufacturers specializing in arylacetic acids, alkylated benzenes, and related compounds. Companies with expertise in Friedel-Crafts alkylation and subsequent functionalization.
2. Epichlorohydrin or Glycidol derivatives: Used to build the propane-1,3-diol backbone.
   • Potential Suppliers: Bulk chemical manufacturers producing epoxides and glycidol. Specialized chiral epoxide suppliers if enantioselective synthesis is employed early.
3. Chiral auxiliaries or catalysts: For asymmetric synthesis routes to achieve the correct stereochemistry.
   • Potential Suppliers: Companies specializing in chiral reagents, ligands, and metal catalysts for asymmetric synthesis. Examples include companies that produce BINAP derivatives or chiral amines.
4. Dodecyl sulfuric acid: The salt-forming agent.
   • Potential Suppliers: Manufacturers of anionic surfactants and sulfuric acid derivatives. Companies that produce lauryl alcohol and then sulfonate it.

Example of an Intermediate Supply Chain Element:

Consider a synthetic route that involves the preparation of 2-(4-octylphenyl)acetonitrile.

• Step 1: Synthesis of 4-octylbenzonitrile from 4-bromobenzonitrile and octylmagnesium bromide (Grignard reaction) or similar coupling.
• Step 2: Conversion of 4-octylbenzonitrile to 2-(4-octylphenyl)acetonitrile.

Suppliers for the starting materials like 4-bromobenzonitrile or benzonitrile and octyl bromide or octanol (which can be converted to the bromide) would be crucial. These are often produced by bulk chemical manufacturers and specialized fine chemical synthesis companies.

Specific Supplier Considerations:

• Regional Specialization: Asia, particularly China and India, is a major hub for fine chemical and intermediate manufacturing due to cost advantages and established infrastructure.
• Quality and GMP Compliance: For intermediates used in later stages of API synthesis, GMP compliance or rigorous quality control is essential to minimize downstream purification challenges and regulatory issues.
• Custom Synthesis: Many CDMOs offer custom synthesis of proprietary intermediates for specific clients, ensuring a secure and tailored supply.

Companies like Sigma-Aldrich (Merck KGaA), Thermo Fisher Scientific, and numerous specialized fine chemical producers would be active in supplying these types of building blocks, though often in non-GMP grades unless specifically contracted. For GMP-grade intermediates directly usable in API synthesis, CDMOs and dedicated API manufacturers are more likely suppliers.

What is the patent landscape for Fingolimod Lauryl Sulfate?

The patent landscape for fingolimod and its lauryl sulfate salt is complex, involving composition of matter patents, formulation patents, and process patents. Understanding these is vital for generic entry and freedom-to-operate assessments.

Key Patent Categories and Their Impact:

1. Composition of Matter Patents:

   • The primary patent covering fingolimod itself (specifically the free base) has expired in major markets. For instance, the compound was first patented by Novartis. The expiration of these core patents opens the door for generic manufacturers.
   • Example: US Patent 5,604,229, initially covering fingolimod, has expired.

2. Salt Form Patents:

   • Patents may cover specific salt forms of fingolimod, such as the lauryl sulfate salt, or specific crystalline forms (polymorphs) of the salt. These can extend market exclusivity.
   • Example: Patents covering the lauryl sulfate salt form or specific advantageous polymorphs of fingolimod lauryl sulfate would be critical. These patents often claim improved stability, solubility, or manufacturing characteristics.

3. Formulation Patents:

   • Patents related to the final dosage form (e.g., capsules) and specific excipients used in the Gilenya® formulation can provide secondary exclusivity. These might cover novel delivery systems or synergistic combinations of ingredients.
   • Example: Patents on the specific capsule composition or manufacturing process of Gilenya® could be relevant.

4. Process Patents:

   • These patents cover specific methods of synthesizing fingolimod or its lauryl sulfate salt. This includes novel synthetic routes, improved purification techniques, or specific stereoselective synthesis methods.
   • Impact on Generics: Generic manufacturers must ensure their manufacturing processes do not infringe on any active, valid process patents. Often, generic companies develop alternative, non-infringing synthetic routes.
   • Example: A patent describing a novel catalyst for a key reaction step or a unique crystallization process for fingolimod lauryl sulfate would be a process patent.

Patent Expiry and Generic Competition:

The expiration of key composition of matter patents is the primary driver for generic competition. However, the presence of strong salt form, polymorph, formulation, or process patents can delay or complicate generic market entry.

• Global Patent Landscape: Patent protection is territorial. Companies must analyze patent portfolios in each target market (e.g., US, Europe, Japan, Canada).
• Litigation: Patent disputes are common in the pharmaceutical industry. Generic companies often challenge existing patents, and originators defend them vigorously. Any active litigation or past successful challenges are critical data points.
• Data Exclusivity: In addition to patent protection, regulatory data exclusivity periods can also prevent generic approval for a certain time after the originator's drug is approved, regardless of patent status.

Key Players in Patent Defense and Assertion:

• Novartis AG: As the originator, Novartis actively seeks to protect its market exclusivity through patent filings and enforcement.
• Generic Pharmaceutical Companies: Companies like Teva Pharmaceutical Industries, Mylan (now Viatris), Sun Pharmaceutical Industries, and others are actively involved in developing generic versions, which often involves challenging existing patents or developing non-infringing processes.
• Specialized Patent Firms: Law firms with expertise in pharmaceutical patent law are instrumental in both asserting and defending these intellectual property rights.

Companies must perform comprehensive freedom-to-operate (FTO) analyses to identify any potential patent infringements before launching a generic product or investing in specific manufacturing processes. This typically involves detailed patent searching, claim interpretation, and legal opinion.

Key Takeaways

The supply chain for fingolimod lauryl sulfate is underpinned by a network of specialized API manufacturers and intermediate suppliers. Novartis AG, the originator, maintains its manufacturing control, while a range of CDMOs and generic API producers serve the broader market. Key intermediates, such as 4-octylphenylacetic acid derivatives and epoxides, are sourced from fine chemical manufacturers globally, with a significant presence in Asia. The patent landscape is characterized by expired composition of matter patents, but ongoing protection for specific salt forms, polymorphs, formulations, and manufacturing processes influences generic market entry. Vigilant monitoring of patent expirations, regulatory approvals, and potential patent litigation is essential for any entity operating within the fingolimod lauryl sulfate market.

FAQs

1. When did the primary composition of matter patent for fingolimod expire in the United States? The primary composition of matter patent for fingolimod, US Patent 5,604,229, expired in 2011.

2. What are the main regulatory requirements for API manufacturers of fingolimod lauryl sulfate? API manufacturers must adhere to current Good Manufacturing Practices (cGMP) as mandated by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other national health authorities. This includes stringent quality control, robust documentation, and validated manufacturing processes.

3. How does the development of alternative synthetic routes mitigate patent infringement risks for generic fingolimod lauryl sulfate? Generic companies develop alternative synthetic routes to avoid infringing on any existing process patents held by the originator or other parties. This involves identifying different chemical transformations, reagents, or catalysts to produce the same API without violating intellectual property rights.

4. Beyond large pharmaceutical companies, what types of companies are typically involved in the supply of critical chemical intermediates for fingolimod synthesis? Specialized fine chemical manufacturers, custom synthesis providers, and chemical distributors that focus on pharmaceutical building blocks and reagents are typically involved in supplying critical chemical intermediates.

5. Can Novartis continue to market Gilenya® even if generic versions enter the market? Yes, Novartis can continue to market Gilenya® alongside generic competitors. However, generic entry typically leads to significant price erosion and a reduction in market share for the originator's brand. Novartis may also leverage any remaining formulation or regulatory exclusivities.

Citations

[1] U.S. Patent 5,604,229. (1997). US Patent and Trademark Office. [2] European Medicines Agency. (n.d.). Gilenya. Retrieved from EMA website. [3] U.S. Food and Drug Administration. (n.d.). Gilenya. Retrieved from FDA Orange Book.